vs
Side-by-side financial comparison of Boston Scientific (BSX) and Cintas (CTAS). Click either name above to swap in a different company.
Cintas is the larger business by last-quarter revenue ($6.4B vs $5.2B, roughly 1.2× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 7.8%, a 17.9% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 8.9%). Over the past eight quarters, Cintas's revenue compounded faster (61.2% CAGR vs 12.4%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Cintas Corporation is an American corporation headquartered in Mason, Ohio, which provides a range of products and services to businesses including uniforms, mats, mops, cleaning and restroom supplies, first aid and safety products, fire extinguishers and testing, and safety courses. Cintas is a publicly held company traded on the Nasdaq Global Select Market under the symbol CTAS and is a component of the S&P 500 Index.
BSX vs CTAS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $6.4B |
| Net Profit | $1.3B | $502.5M |
| Gross Margin | 69.5% | 83.1% |
| Operating Margin | — | 10.3% |
| Net Margin | 25.7% | 7.8% |
| Revenue YoY | 11.6% | 8.9% |
| Net Profit YoY | — | 8.4% |
| EPS (diluted) | $0.90 | $1.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $6.4B | ||
| Q4 25 | $5.3B | $2.8B | ||
| Q3 25 | $5.1B | $2.7B | ||
| Q2 25 | $5.1B | $2.7B | ||
| Q1 25 | $4.7B | $2.6B | ||
| Q4 24 | $4.6B | $2.6B | ||
| Q3 24 | $4.2B | $2.5B | ||
| Q2 24 | $4.1B | $2.5B |
| Q1 26 | $1.3B | $502.5M | ||
| Q4 25 | $670.0M | $495.3M | ||
| Q3 25 | $755.0M | $491.1M | ||
| Q2 25 | $795.0M | $448.3M | ||
| Q1 25 | $672.0M | $463.5M | ||
| Q4 24 | $563.0M | $448.5M | ||
| Q3 24 | $468.0M | $452.0M | ||
| Q2 24 | $322.0M | $414.3M |
| Q1 26 | 69.5% | 83.1% | ||
| Q4 25 | 69.6% | 50.4% | ||
| Q3 25 | 69.9% | 50.3% | ||
| Q2 25 | 67.7% | 49.7% | ||
| Q1 25 | 68.8% | 50.6% | ||
| Q4 24 | 67.8% | 49.8% | ||
| Q3 24 | 68.8% | 50.1% | ||
| Q2 24 | 69.2% | — |
| Q1 26 | — | 10.3% | ||
| Q4 25 | 15.6% | 23.4% | ||
| Q3 25 | 20.7% | 22.7% | ||
| Q2 25 | 16.2% | 22.4% | ||
| Q1 25 | 19.8% | 23.4% | ||
| Q4 24 | 14.8% | 23.1% | ||
| Q3 24 | 17.4% | 22.4% | ||
| Q2 24 | 12.6% | 22.2% |
| Q1 26 | 25.7% | 7.8% | ||
| Q4 25 | 12.7% | 17.7% | ||
| Q3 25 | 14.9% | 18.1% | ||
| Q2 25 | 15.7% | 16.8% | ||
| Q1 25 | 14.4% | 17.8% | ||
| Q4 24 | 12.3% | 17.5% | ||
| Q3 24 | 11.1% | 18.1% | ||
| Q2 24 | 7.8% | 16.8% |
| Q1 26 | $0.90 | $1.24 | ||
| Q4 25 | $0.45 | $1.21 | ||
| Q3 25 | $0.51 | $1.20 | ||
| Q2 25 | $0.53 | $1.08 | ||
| Q1 25 | $0.45 | $1.13 | ||
| Q4 24 | $0.38 | $1.09 | ||
| Q3 24 | $0.32 | $1.10 | ||
| Q2 24 | $0.22 | $4.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $183.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.8B |
| Total Assets | — | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $183.2M | ||
| Q4 25 | $2.0B | $200.8M | ||
| Q3 25 | $1.3B | $138.1M | ||
| Q2 25 | $534.0M | $264.0M | ||
| Q1 25 | $725.0M | $243.4M | ||
| Q4 24 | $414.0M | $122.4M | ||
| Q3 24 | $2.5B | $101.4M | ||
| Q2 24 | $2.9B | $342.0M |
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $2.4B | ||
| Q3 25 | $11.1B | $2.4B | ||
| Q2 25 | $11.1B | $2.4B | ||
| Q1 25 | $10.5B | $2.0B | ||
| Q4 24 | $9.0B | $2.0B | ||
| Q3 24 | $9.2B | $2.0B | ||
| Q2 24 | $9.0B | $2.0B |
| Q1 26 | — | $4.8B | ||
| Q4 25 | $24.2B | $4.5B | ||
| Q3 25 | $23.4B | $4.8B | ||
| Q2 25 | $22.4B | $4.7B | ||
| Q1 25 | $22.2B | $4.6B | ||
| Q4 24 | $21.8B | $4.3B | ||
| Q3 24 | $20.7B | $4.0B | ||
| Q2 24 | $20.4B | $4.3B |
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $10.1B | ||
| Q3 25 | $42.7B | $9.8B | ||
| Q2 25 | $41.6B | $9.8B | ||
| Q1 25 | $40.1B | $9.6B | ||
| Q4 24 | $39.4B | $9.4B | ||
| Q3 24 | $38.1B | $9.1B | ||
| Q2 24 | $37.1B | $9.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 0.54× | ||
| Q3 25 | 0.48× | 0.51× | ||
| Q2 25 | 0.50× | 0.52× | ||
| Q1 25 | 0.47× | 0.44× | ||
| Q4 24 | 0.41× | 0.47× | ||
| Q3 24 | 0.45× | 0.50× | ||
| Q2 24 | 0.44× | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $1.6B |
| Free Cash FlowOCF − Capex | — | $1.3B |
| FCF MarginFCF / Revenue | — | 19.7% |
| Capex IntensityCapex / Revenue | — | 4.7% |
| Cash ConversionOCF / Net Profit | — | 3.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.4B | $531.2M | ||
| Q3 25 | $1.3B | $414.5M | ||
| Q2 25 | $1.3B | $635.7M | ||
| Q1 25 | $541.0M | $622.0M | ||
| Q4 24 | $1.5B | $441.4M | ||
| Q3 24 | $1.0B | $466.7M | ||
| Q2 24 | $813.0M | $693.0M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.0B | $425.0M | ||
| Q3 25 | $1.2B | $312.5M | ||
| Q2 25 | $1.1B | $521.1M | ||
| Q1 25 | $354.0M | $522.1M | ||
| Q4 24 | $1.2B | $340.0M | ||
| Q3 24 | $823.0M | $373.8M | ||
| Q2 24 | $658.0M | $591.1M |
| Q1 26 | — | 19.7% | ||
| Q4 25 | 19.2% | 15.2% | ||
| Q3 25 | 22.9% | 11.5% | ||
| Q2 25 | 22.3% | 19.5% | ||
| Q1 25 | 7.6% | 20.0% | ||
| Q4 24 | 25.8% | 13.3% | ||
| Q3 24 | 19.6% | 14.9% | ||
| Q2 24 | 16.0% | 23.9% |
| Q1 26 | — | 4.7% | ||
| Q4 25 | 6.6% | 3.8% | ||
| Q3 25 | 3.6% | 3.8% | ||
| Q2 25 | 3.1% | 4.3% | ||
| Q1 25 | 4.0% | 3.8% | ||
| Q4 24 | 6.1% | 4.0% | ||
| Q3 24 | 4.3% | 3.7% | ||
| Q2 24 | 3.8% | 4.1% |
| Q1 26 | — | 3.12× | ||
| Q4 25 | 2.04× | 1.07× | ||
| Q3 25 | 1.78× | 0.84× | ||
| Q2 25 | 1.62× | 1.42× | ||
| Q1 25 | 0.81× | 1.34× | ||
| Q4 24 | 2.59× | 0.98× | ||
| Q3 24 | 2.14× | 1.03× | ||
| Q2 24 | 2.52× | 1.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.5B | 67% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
CTAS
Segment breakdown not available.
